1. DISEASE CHARACTERISTICS 1.1 Name of the disease (synonyms) See Table 1 , column 1-'Name of the disease'.
OMIM# of the disease
See Table 1 , column 2-'OMIM# of the disease'.
1.3 Name of the analysed genes or DNA/chromosome segments and OMIM# of the gene(s) 1.3.1 Core genes (irrespective if being tested by Sanger sequencing or next-generation sequencing) See Table 1 , column 4-'Associated gene(s)' and column 5-'OMIM# of associated gene(s)'.
Additional genes (if tested by next-generation sequencing,
including whole-exome/-genome sequencing and panel sequencing) See Table 2 , column 1-'Gene' and column 3-'OMIM# of gene'.
Mutational spectrum
Isolated microphthalmia is rare; most patients have associated ocular anomalies (complex), such as ocular coloboma, cataract and anterior segment dysgenesis. Nearly 80% of cases are associated with multisystemic features forming part of a syndrome. [1] [2] [3] [4] Only isolated and complex (non-syndromic) microphthalmia will be discussed (see Clinical Utility Gene Card for syndromic microphthalmia). There is a complex aetiology with chromosomal, monogenic and environmental causes identified. It is clinically and genetically heterogeneous, and may be inherited in an autosomal-dominant, -recessive or X-linked recessive manner, although most cases of non-syndromic microphthalmia are sporadic. The occurrence of de novo mutations, mosaicism and incomplete penetrance makes prediction of the inheritance pattern difficult. Chromosomal duplications, deletions and translocations have been identified; a locus for autosomaldominant microphthalmia has been mapped to 15q12-15, 5 and for autosomal-recessive microphthalmia at 14q32. 6, 7 Autosomal-recessive VSX2 variants (causing MCOP2) account for~2% of isolated microphthalmia cases, and are predominantly missense. However, deletion of exon 3 has also been described. [8] [9] [10] Autosomal-recessive variants in RAX (MCOP3) [10] [11] [12] and ALDH1A3 (MCOP8) can be missense, nonsense or frameshift, with some splice donor variants. A RAX gene deletion has also been described in one patient with bilateral anophthalmia, with no other ocular or systemic abnormalities reported. 10 RAX mutations account for~2% of inherited anophthalmia/microphthalmia cases. 11 Only missense variants have been found in GDF6 (MCOP4) 10, 13 and GDF3 (MCOP7), 14 and are inherited in an autosomal-dominant manner. Homozygous or compound heterozygous variants in MFRP (MCOP5) [15] [16] [17] [18] [19] or PRSS56 (MCOP6) [20] [21] [22] [23] are associated with autosomal-recessive posterior microphthalmia, which defines a rare distinct phenotype restricted primarily to the posterior segment of the eye. Patients with MFRP variants also develop a progressive rod cone dystrophy. 18 Missense, nonsense and frameshift variants, plus splice donor variants have been described for both these genes.
COL4A1 (NM_ 001845.5: c.2317G4A (p.Gly773Arg); c.2122G4A (p.Gly708Arg)) variants are often reported in cases of brain small vessel disease with or without ocular anomalies, however, variants have been found in siblings with microphthalmia, other ocular anomalies, but no/few neurologic symptoms. 24 Isolated microphthalmia with coloboma is a heterogeneous condition. Cases without systemic involvement are predominantly associated with autosomaldominant transmission, although a few recessive cases have been described. MCOPCB1 has been mapped to the X chromosome, 25 and MCOPCB2 to chromosome 15q12-q15. 26 Homozygosity for missense and a splice variant in VSX2 have been described in MCOPCB3 cases. 27, 28 MCOPCB4 is isolated microphthalmia associated with colobomatous cyst and is transmitted as an autosomal-recessive trait. The genetic cause remains unknown. A heterozygous 24 bp deletion in the coding region of SHH has been identified in MCOPCB5 patients. 29, 30 Heterozygous missense variants in GDF3 14 and ABCB6 31 have been described in patients with MCO PCB6 and MCOPCB7, respectively. Homozygous splice variant (NM_001080477.3: c.2968-2A4T (p.Val990Cysfs)) 32 and frameshift loss of function variant (NM_001080477.3: c.2083dupA (p.Thr695Asnfs)) 33 in TENM3 result in MCOPCB9. A missense variant in RBP4 (NM_006744.3: c.217G4A (p.Ala73Thr)) has been associated with MCOPCB10. 34 Many specific variants may cause varied phenotypes, for example, NM_001142617.1: c.1157G4A and c.1156G4A (p.Gly304Lys) in STRA6 causes MCOPCB8 (isolated microphthalmia and coloboma) and Matthew-Wood syndrome (bilateral anophthalmia with pulmonary agenesis and other associated systemic defects). 35 Phenotypic findings in patients presenting with microphthalmia and congenital cataract (MCOPCT1) also include mental retardation and an individual with congenital heart disease. 36, 37 Patients with OTX2 variants have been described with specific hippocampal abnormalities, and phenotypic findings in patients affected by RAX variants include 40 Consequently, the contribution of TMX3 variants to MCOPCB1 has been suggested, but remains to be confirmed.
Nanophthalmos is a subtype of simple microphthalmos. Autosomalrecessive nanophthalmos 2 (NNO2) has been associated with homozygosity for a nonsense (NM_031433.3: c.523C4T, (p.Gln175Ter)) or frameshift (NM_031433.3: c.1143insC (p. Gly383Ter)) variant, and compound heterozygosity for a frameshift (NM_031433.3: c.498delC (p.Asn167Thrfs)) or a missense (NM_031433.3: c.545 T4C (p.Ile182Thr)) variant in MFRP. 41 Additional complications can develop, including angle-closure glaucoma, cystic oedema and retinal detachment. More recently, two segregating missense variants (NM_015544.2: c.577G4C (p.Ala193Pro); c.587A4C (p.His196Pro)) and a 34 bp heterozygous deletion (NM_015544.2: c.236_263+6del34) in TMEM98 have been described in autosomal-dominant nanophthalmos (NNO4) pedigrees. 42, 43 Of the monogenic causes of anophthalmia/microphthalmia, SOX2 has been implicated as a major causative gene, in which variants account for 15-20% of autosomal-dominant cases. 44 However, patients with SOX2 variants usually present with other systemic malformations; the contribution of SOX2 variants to isolated microphthalmia specifically remains unknown. The majority of SOX2 sequence variants are de novo; nonsense, missense, frameshift and whole-gene deletions have been reported. 10, 45, 46 Like SOX2, the majority of OTX2 variants are inherited nonsense and frameshift variants leading to haploinsufficiency, with some reports of whole-gene deletions. 10, 47 Patients often present with additional brain abnormalities. In view that variants in the genes listed in Table 2 cause a wide range of ocular phenotypes with different expressivity, their molecular screening must be recommended.
All data were mined from primary literature or curated genomic and phenotype databases, including ClinVar, public archive of interpretations of clinically relevant variants (http://www.ncbi.nlm. nih.gov/clinvar/); GeneReviews (http://www.ncbi.nlm.nih.gov/books/ NBK1116/); The Human Gene Mutation Database, HGMD (http:// www.hgmd.org/) and Online Mendelian Inheritance in Man, OMIM (http://omim.org/). Novel data should be shared through these databases. They were last accessed on 21 November 2016.
Analytical validation
Sequencing of both DNA strands. Disease-causing variants should be confirmed using genomic DNA from a new extraction. Causative variants found with next-generation sequencing should be verified using Sanger sequencing or other specific molecular methods (eg, PCR digest); for further details, see the Eurogentest Guideline. It is important to look for segregation to determine whether the variant is de novo in isolated cases, providing a higher likelihood it is pathogenic. In clinical practice, array comparative genomic hybridisation (aCGH) or multiplex ligation-dependent probe amplification assay may be performed initially to detect deletions or duplications. Some molecular service labs also offer fluorescence in situ hybridisation to identify rearrangements or copy-number variation.
1.6 Estimated frequency of the disease (incidence at birth ('birth prevalence') or population prevalence) If known to be variable between ethnic groups, please report:
The birth prevalence of microphthalmos ranges from 2 to 17 per 100 000. [48] [49] [50] [51] [52] [53] In a prospective UK incidence study over 18 months, 135 confirmed cases of microphthalmia, anophthalmia and ocular coloboma (MAC) were reported in children under 16 years of age; microphthalmia was present in 66 (48.9%) children; isolated in 31 (23%) and mixed in 35 (25.9%). 54 Microphthalmia was reported in 3.2-11.2% of blind children worldwide in 2006. 4 Epidemiological data suggest risk factors for microphthalmia are maternal age over 40, multiple births, infants of low birthweight and low gestational age. 4, 52, 55 There is no predilection with regard to race or gender. 52, 55 Isolated microphthalmia is most commonly unilateral. 55 Comment: Because of the time constraints, such as pregnancy, panel diagnostic or whole-exome sequencing, or whole-genome sequencing (WES/WGS) filtering is preferred if there is a request for prenatal diagnosis (which is rare). 
Diagnostic setting

TEST CHARACTERISTICS
If tested by conventional Sanger sequencing
Less than 100%. The proportion is likely o100%, because primers may be localised on sequences containing SNVs or rare variants, which results in a preferential amplification of one allele (allele dropout).
A supplementary deletion/duplication diagnostic test should be performed for genes with a known proportion of large genomic deletions/duplications as outlined in the section 'Analytical validation'.
If tested by next-generation sequencing
Less than 100%. The proportion is likely o100%, because there might be disease-causing variants in regions that could not be enriched and/ or sequenced by next-generation sequencing owing to suboptimal coverage of some regions of interest with this technology, but depending on next-generation sequencing strategy. If ampliconbased enrichment strategies are being used, primers may be localised on SNVs or rare variants, which results in preferential amplification of one allele. In patients with a highly suggestive phenotype in whom testing for specific gene alterations proves negative, a supplementary deletion/duplication diagnostic test should be performed for genes with a known proportion of large genomic deletions/duplications as outlined in the section 'Analytical validation'.
Analytical specificity (proportion of negative tests if the genotype is not present)
If tested by conventional Sanger sequencing
Nearly 100%. False positives may at the most arise owing to misinterpretation of rare polymorphic variants.
If tested by next-generation sequencing
Less than 100%. The risk of false positives owing to misinterpretation of rare polymorphic variants may be higher compared with Sanger sequencing because of greater number of analysed genes.
Clinical sensitivity (proportion of positive tests if the disease is present)
The clinical sensitivity can be dependent on variable factors such as age or family history. In such cases, a general statement should be given, even if a quantification can only be made case by case.
If tested by conventional Sanger sequencing
Of those patients that undergo genetic testing of known causative genes with Sanger sequencing, o10% of patients with isolated microphthalmia receive a molecular diagnosis and these are predominantly bilateral severe cases.
Most studies group microphthalmia with MAC, and therefore the most common causative genes are SOX2, OTX2, PAX6 and GDF6 contributing up to 10, 3, 2.5 and 8%, respectively. 56 These are often syndromic cases and so the actual contribution to isolated microphthalmia is likely to be much lower.
If tested by next-generation sequencing
See section 'If tested by conventional Sanger sequencing'. Mutation detection rates are higher when combined WES with array aCGH and high-resolution analysis of intragenic microdeletions and microduplications are performed. WGS may aid in the detection of pathogenic variants in the promotor region, introns and other non-coding regulatory elements, and provide better coverage than exome sequencing. Regulatory element disruption in microphthalmia remains largely uncharacterised.
Clinical specificity (proportion of negative tests if the disease is not present)
The clinical specificity can be dependent on variable factors such as age or family history. In such cases, a general statement should be given, even if a quantification can only be made case by case.
If tested by conventional Sanger sequencing
Unknown, however, if microphthalmia is not present, it is unlikely that a positive test will be detected.
If tested by next-generation sequencing
See section 'If tested by conventional Sanger sequencing'.
Positive clinical predictive value (life time risk to develop the disease if the test is positive)
This is a congenital anomaly of the eye, therefore patients will be born with this defect, therefore nearly 100%, however variable expressivity has been noted.
Negative clinical predictive value (probability of not developing the disease if the test is negative)
Assume an increased risk based on family history for a non-affected person. Allelic and locus heterogeneity may need to be considered.
Index case in that family had been tested: Nearly 100%. If the non-affected relative is not a carrier of an identified disease-causing mutation, they have no increased risk, except a small risk related to the prevalence in the general population.
Index case in that family had not been tested: Unknown.
3. CLINICAL UTILITY 3.1 (Differential) diagnostics: The tested person is clinically affected (To be answered if in 1.7 'A' was marked)
Can a diagnosis be made other than through a genetic test?
No. □ (continue with 3. 
Describe the burden of alternative diagnostic methods to the patient
The definition of microphthalmia is heterogenous, however, an axial length (AL) of o21 mm in adults and o19 mm in a 1-year-old is most widely accepted as it represents a reduction of 2 SD or more below normal. Microphthalmia can be detected using ultrasound during the second trimester, or after birth in conjunction with clinical examination. Microphthalmia can be associated with microcornea, which is defined as a horizontal diameter o9 mm in a newborn and o10 mm in children 2 years and older. Posterior microphthalmia is a rare subset of microphthalmia in which the total AL of the eyeball is reduced although anterior segment dimensions including corneal diameter, anterior chamber depth and anteroposterior length of the lens are normal, also detected by ultrasound. Nanophthalmia, a second rare subset of microphthalmia, is classically distinguished from posterior microphthalmia based on the presence of decreased anterior chamber dimensions. Although a diagnosis of microphthalmia can be made relatively easily and cost-effectively, if this anomaly is seen, children should be investigated within a multidisciplinary team, including paediatricians and clinical geneticists, to ensure this is not part of a syndrome.
Further monitoring may be required as syndromic manifestations may present later in childhood. Yes. Germline mosaicism and/or variable penetrance render the prediction of recurrence risk difficult in monogenic microphthalmic individuals, however, molecular genetic studies for known variants are possible on amniotic fluid foetal cells withdrawn after 14 weeks of gestation or on chronic villus sampling at 10-12 weeks gestation, and can facilitate the diagnosis of microphthalmia. In addition, transvaginal ultrasonography enables the detection of microphthalmia from 12 weeks gestation; 57 the maximal coronal or axial planes of the orbit are measured, and compared with established eye growth charts. 58 
IF APPLICABLE, FURTHER CONSEQUENCES OF TESTING
Please assume that the result of a genetic test has no immediate medical consequences. Is there any evidence that a genetic test is nevertheless useful for the patient or his/her relatives? (Please describe) Beyond potentially defining recurrence risk information dependent on the cause and mode of inheritance, identifying the genetic aetiology may guide genetic counselling. It also contributes to the classification of syndromic or non-syndromic microphthalmia, thereby guiding any subsequent investigations for affected patients.
